Douglas Strassler, Digital Content Editor

Different clinical and neurobiologic pathways may be involved in treatment-resistant schizophrenia as it is not a homogeneous subgroup within the schizophrenia spectrum.

Augmentation therapy for treatment-resistant major depressive disorder includes multiple options with different strengths and limitations.

For patients with bipolar disorder and major depressive disorder, reduction in dose of antipsychotic medication could lead to an increased rate of hospitalization.

Dr. Grant also acknowledged that while some patients are uncomfortable with the fact that medication doses for OCD are higher than they are for depression, those higher doses are crucial for symptomatic improvement.

Michael Thase, MD, discusses therapy options as well as side effect management for individuals with major depressive disorder.